Literature DB >> 4838912

L-dopa and arousal.

T B Horvath, R A Meares.   

Abstract

In 10 patients with Parkinsonism, treatment with L-dopa was associated with a rise in the skin conductance level and its fluctuations, an increased electromyographic activity in the frontalis muscle, and with faster reaction times. The change of skin conductance in response to a loud noise also increased and its habituation to the repetition of the stimulus was delayed. One patient developed a schizophreniform psychosis and showed high arousal and absent habituation. It is possible that dopamine is the transmitter associated with the arousal reaction and that it plays a part in the pathogenesis of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4838912      PMCID: PMC494672          DOI: 10.1136/jnnp.37.4.416

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  34 in total

1.  A comparative study of disordered attention in schizophrenia.

Authors:  J CHAPMAN; A McGHIE
Journal:  J Ment Sci       Date:  1962-07

2.  Psychological phenomena and the electroencephalogram.

Authors:  D B LINDSLEY
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1952-11

Review 3.  Catecholamines in the brain as mediators of amphetamine psychosis.

Authors:  S H Snyder
Journal:  Arch Gen Psychiatry       Date:  1972-08

4.  Stereotaxic mapping of the monoamine pathways in the rat brain.

Authors:  U Ungerstedt
Journal:  Acta Physiol Scand Suppl       Date:  1971

5.  A physiological difference between hallucinosis and schizophrenia.

Authors:  R Meares; T Horvath
Journal:  Br J Psychiatry       Date:  1973-06       Impact factor: 9.319

Review 6.  The catecholamine hypothesis of affective disorders: a review of supporting evidence.

Authors:  J J Schildkraut
Journal:  Am J Psychiatry       Date:  1965-11       Impact factor: 18.112

7.  Treatment of parkinsonism with levodopa.

Authors:  M D Yahr; R C Duvoisin; M J Schear; R E Barrett; M M Hoehn
Journal:  Arch Neurol       Date:  1969-10

8.  Memory disturbance and the Parkinson syndrome.

Authors:  J W Warburton
Journal:  Br J Med Psychol       Date:  1967-06

9.  Levodopa's awakening effect on patients with Parkinsonism.

Authors:  G G Marsh; C M Markham; R Ansel
Journal:  J Neurol Neurosurg Psychiatry       Date:  1971-06       Impact factor: 10.154

Review 10.  Dopamine (3-hydroxytyramine) and brain function.

Authors:  O Hornykiewicz
Journal:  Pharmacol Rev       Date:  1966-06       Impact factor: 25.468

View more
  7 in total

1.  Dopaminergic stimulation in unilateral neglect.

Authors:  G Geminiani; G Bottini; R Sterzi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-09       Impact factor: 10.154

2.  Parkinson's disease in the elderly: response to and optimal spacing of night time dosing with levodopa.

Authors:  A L Leeman; C J O'Neill; P W Nicholson; A A Deshmukh; M J Denham; J P Royston; R J Dobbs; S M Dobbs
Journal:  Br J Clin Pharmacol       Date:  1987-11       Impact factor: 4.335

3.  Recognition memory in Parkinson's disease.

Authors:  K A Flowers; I Pearce; J M Pearce
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-11       Impact factor: 10.154

4.  Akinesia in Parkinsonism. Relation between spontaneous movement (other than tremor) and voluntary movements made on command.

Authors:  C H Meyer
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-07       Impact factor: 10.154

5.  Dopamine-sensitive alternation and collateral behaviour in a Y-maze: effects of d-amphetamine and haloperidol.

Authors:  R Oades; K Taghzouti; H Simon; M Le Moal
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

6.  Cognitive deficits associated with chronic hepatic encephalopathy and their response to levodopa.

Authors:  A Elithorn; M Lunzer; J Weinman
Journal:  J Neurol Neurosurg Psychiatry       Date:  1975-08       Impact factor: 10.154

7.  Usefulness of movement time in the assessment of Parkinson's disease.

Authors:  M Zappia; R Montesanti; R Colao; A Quattrone
Journal:  J Neurol       Date:  1994-08       Impact factor: 4.849

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.